Survival outcomes in iron chelated and non-chelated patients with lower-risk myelodysplastic syndromes: Review and pooled analysis of observational studies

Affiliations

• ¹ Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, Tucson, AZ, USA; University of Arizona Cancer Center, Tucson, AZ, USA; Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ, USA; Department of Family and Community Medicine, College of Medicine, University of Arizona, Tucson, AZ, USA; Matrix45, Tucson, AZ, USA. Electronic address: [email protected].
• ² Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, Tucson, AZ, USA; King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
• ³ H. Lee Moffitt Cancer Center, Tampa, FL, USA.
• ⁴ College of Nursing, Catholic University of Korea, Seoul, Republic of Korea.
• ⁵ University of Arizona Cancer Center, Tucson, AZ, USA; Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ, USA.
• ⁶ Matrix45, Tucson, AZ, USA.